The Associate Vice President, Aging owns Lilly’s aging strategy within Mobility and Healthy Aging (MHA), a new pillar within Cardiometabolic Research focused on age-related loss of function in bone, muscle, joint, and the biology of aging. The role is the senior scientific voice for the strategy, providing deep expertise in aging biology—including cellular senescence, proteostasis, mitochondrial dysfunction, chronic inflammation, and epigenetic and molecular measures of biological age—to guide target and mechanism selection, patient and clinical settings, capability development, and portfolio alignment. The position is accountable for the scientific credibility of aging-directed targets and assets in the MHA portfolio and for translating aging biology into medicines with definable patient populations and measurable endpoints. The leader works across bone, muscle, and joint biology to identify interventions that address aging mechanisms and produce functional benefits across tissues, while collaborating with scientists and leaders throughout Lilly on approaches to aging and age-related disorders. This role combines scientific leadership, external influence, and portfolio strategy. It guides aging research and development programs, biomarkers, models, assays, and translational tools; represents Lilly in the aging research community; and advises on external opportunities and collaborations. The role also brings clinical and regulatory judgment to strategy, recognizing that aging itself is not an approvable indication and that programs must be grounded in appropriate tissue and disease contexts.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Executive
Education Level
Ph.D. or professional degree